Market Research Report
Global Liquid Biopsy Market: Focus on Market Segmentation by Product Type, Indication Type, Technology, Biomarker, Clinical Applications, Sample Type, Usage, Workflow, Geographical & Competitive Landscape-Analysis & Forecast, 2020 - 2030
|Published by||BIS Research Inc.||Product code||962421|
|Published||Content info||302 Pages
Delivery time: 1-2 business days
|Global Liquid Biopsy Market: Focus on Market Segmentation by Product Type, Indication Type, Technology, Biomarker, Clinical Applications, Sample Type, Usage, Workflow, Geographical & Competitive Landscape-Analysis & Forecast, 2020 - 2030|
|Published: September 25, 2020||Content info: 302 Pages||
Global Liquid Biopsy Market:
Focus on Market Segmentation by Product Type, by Indication Type, by Technology, by Biomarker, by Clinical Applications, by Sample Type, by Usage, By Workflow, Geographical and Competitive Landscape - Analysis and Forecast, 2020-2030.
"Global Liquid Biopsy Market to Reach $12.9 Billion by 2030."
GUARDANT HEALTH, Biocept, Bio-Rad Laboratories, Cynvenio Biosystems, Chronix Biomedical,Illumina ,and Neogenomics Laboratories, among others.
Liquid biopsy is anon-invasive clinical alternative to surgical tissue biopsies. Performing liquid biopsies enables physicians to discover a wider range of information about tumors through the assessment of blood or other fluid-basedsamples from a perspective cancer patient.
Traditionally, the liquid biopsy services were mainly focused on oncology settings, such as treatment decisions, recurrence monitoring, and screening. However, with the advent of new players in the liquid biopsy market, transplant rejection assessment services and infectious disease services based on liquid biopsies areset to become eminent parts of current practices. Several players, such as GUARDANT HEALTH, CareDX, and Chronix Biomedical,currently offer these services in the market. The entry of new players in the market, coupled up with the increased innovation pertaining to cost mitigation and resource output maximization,has been transforming the market currently.
The existing market of liquid biopsy is favored by multiple factors, includingrising prevalence of cancers, increasing adoption of inorganic growth strategies in the market, and increased NCI funding.
Within the research report, the market is segmented on the basis of technology offered by key players (NGS, PCR, FISH, and other technologies), workflow (sample preparation, library preparation, sequencing, and data analysis), usage (RUO and diagnostic), sample (blood and non-blood samples), circulating biomarker (circulating tumor cells, cell-free DNA, circulating RNA, exosomes and extracellular vesicles, and others), product (test/services, kits and consumables, and instruments), oncology indication type (lung cancer, breast cancer, prostate cancer, colorectal cancer, melanoma, and other cancers), clinical application (treatment monitoring, prognosis and recurrence monitoring, treatment selection, diagnosis, and screening), and region (North America, Europe, Latin America and Middle East, and Asia-Pacific). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360° coverage of the domain.
Major players, including GUARDANT HEALTH, Biocept, Bio-Rad Laboratories, and Cynvenio Biosystems, among others, led the number of synergistic developments (partnerships and alliances) witnessed in the market. On the basis of region, North America is expected to retain a leading position throughout the forecast period 2020-2030, followed byEurope. The high growth is attributed to the presence of leading industry players in North America, coupled up with therising prevalenceof cancer.